Programming the immunological properties of mRNA vaccines for cancer
- 19 June 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 26 (11) , 837-850
Abstract
Messenger RNA (mRNA) vaccines are a transformative platform for inducing antigen-specific T cell and B cell responses that are now being trialled in oncology. Here we propose an immunological framework that reconciles four axes controlling the efficacy of mRNA cancer vaccines: adjuvanticity versus immunopathology, antigen immunogenicity versus tolerance, adaptive immune memory versus exhaustion, and beneficial versus maladaptive trained immunity. We argue that mRNA vaccines should be viewed as programmable constructs in which nucleoside chemistry, delivery platforms and dosing schedules can be manipulated to tune these four axes by modulating antigen identity and decay, costimulation, cytokine tone and innate stimulation. By fitting recent mechanistic and translational insights into this framework, we outline design principles for positioning mRNA cancer vaccines within an optimal window of immune activation that supports durable, tumour-specific immunity while minimizing T cell exhaustion, tolerance and systemic toxicity.Keywords
This publication has 127 references indexed in Scilit:
- Signatures of Trained Immunity Following mRNA Vaccination: Differences Between mRNA-1273 and BNT162b2Journal of Clinical Immunology, 2025
- Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune CellsAdvanced Materials, 2025
- Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In SituJAMA Oncology, 2025
- Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsCancer Cell, 2024
- Development of Mannosylated Lipid Nanoparticles for mRNA Cancer Vaccine with High Antigen Presentation Efficiency and Immunomodulatory CapabilityAngewandte Chemie, 2024
- A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunityCancer Cell, 2023
- Optimizing Lipid Nanoparticles for Delivery in PrimatesAdvanced Materials, 2023
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse modelCancer Immunology, Immunotherapy, 2018
- PEGylation as a strategy for improving nanoparticle-based drug and gene deliveryAdvanced Drug Delivery Reviews, 2016